Pfizer reports positive Phase 2 tilrekimig eczema trial data

Pfizer announced detailed results from an ongoing Phase 2 study of tilrekimig in adults with moderate-to-severe atopic dermatitis on October 1, 2026. The trial met its primary endpoint, showing a statistically significant increase in the percentage of patients achieving EASI-75 at Week 16 across all evaluated doses compared to placebo. The findings were presented at the 35th European Academy of Dermatology and Venereology Annual Congress in Vienna, Austria.

Tilrekimig is an investigational trispecific antibody that binds interleukin-4, interleukin-13, and thymic stromal lymphopoietin. It has an extended half-life of about 37 days, intended to support monthly dosing. In Stage 1 of the trial, 62.5% of biologic-naïve patients receiving 450 mg every two weeks achieved EASI-75, compared to 19.9% on placebo. In Stage 2 monthly dosing, EASI-75 was achieved by 58.5% of patients on 400 mg, 61.0% on 200 mg, and 47.8% on 50 mg, compared to 9.1% on placebo.

Clear or almost clear skin (vIGA 0/1) was reached by 30.3% of patients in the 450 mg group versus 11.8% on placebo, and by 26% to 27% across monthly doses compared to 0% for placebo. Treatment-emergent adverse event rates were 46.7% for the 450 mg dose versus 28.9% for placebo in Stage 1, and ranged from 42.2% to 47.8% across monthly doses versus 52.2% for placebo in Stage 2. No serious drug-related adverse events were reported.

Pfizer has already initiated Phase 3 trials for tilrekimig in atopic dermatitis and asthma, including an atopic dermatitis study using dupilumab as an active comparator. The company is also running a Phase 2b/3 trial evaluating the drug in chronic obstructive pulmonary disease.